FDA Updates

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between June 30, 2021, and July 26, 2021.
This section provides a brief overview of new cancer drugs and new indications approved by the FDA between June 30, 2021, and July 26, 2021.
This section provides a brief overview of new cancer drugs and new indications approved by the FDA between May 5, 2021, and May 28, 2021.
This section provides a brief overview of new cancer drugs and new indications approved by the FDA between April 13, 2021, and April 23, 2021.
This section provides a brief overview of new cancer drugs and indications approved by the FDA between February 5, 2021, and February 22, 2021.
This section provides a brief overview of new cancer drugs approved by the FDA between November 25, 2020, and December 18, 2020.
On September 4, 2020, the FDA accelerated the approval of pralsetinib (Gavreto; Blueprint Medicines/Genentech), an oral RET inhibitor, for the treatment of adults with metastatic non–small-cell lung cancer (NSCLC) and RET-activating fusions, as detected by an FDA-approved test.
This section provides a brief overview of new cancer drugs approved by the FDA between July 31, 2020, and September 4, 2020.
This section provides a brief overview of new cancer drugs or new indications approved by the FDA between June 30, 2020, and July 24, 2020.
This section provides a brief overview of new cancer drugs or new indications approved by the FDA between May 26 and June 15, 2020.
Page 1 of 18
Results 1 - 10 of 172